Loading
Healthcare
4 min read
Areas of Expertise :
Biomedical Engineering, Medical Devices, Food And Drug Administration (FDA), Regulatory Compliance, Product Liability
Published Date:
Last Modified Date:
Jurisdiction:
Federal. Ninth Circuit
Court:
Stengel v. Medtronic Inc., 704 F.3d 1224 (9th Cir. 2013), is a significant appellate case addressing federal preemption in medical device litigation and the ability to pursue state-law failure-to-warn claims. The lawsuit involved the Medtronic SynchroMed EL, an implantable drug infusion pump approved through the U.S. Food and Drug Administration's (FDA) premarket approval (PMA) process. After Richard Stengel experienced complications allegedly linked to the device, the plaintiffs challenged Medtronic’s postmarket safety reporting practices. While biomedical engineering issues were relevant, the core legal question concerned whether a state-law claim that paralleled federal regulatory obligations could avoid preemption.
Richard Stengel, a former police officer, was implanted with the Medtronic SynchroMed EL, a Class III medical device intended for targeted drug delivery. The device had received FDA PMA approval and was designed to administer medication into the intrathecal space for chronic pain management.
After implantation, Stengel experienced serious medical complications, including inflammation and paralysis. These conditions were allegedly linked to a malfunction of the catheter component of the infusion pump. The incident raised questions about medical device safety, postmarket performance, and whether Medtronic had properly reported known risks to the FDA.
Stengel and his wife filed a civil lawsuit in federal court, asserting state-law causes of action for defective design and failure to warn. The district court dismissed the claims, ruling that they were preempted under the Medical Device Amendments (MDA) of 1976 due to the device’s FDA-approved status.
The U.S. Court of Appeals for the Ninth Circuit reversed the district court’s decision. It ruled that the plaintiffs’ failure-to-warn claim was not preempted because it was based on a state-law duty that paralleled federal regulations requiring manufacturers to report adverse events to the FDA. The case clarified the application of the “parallel claims” doctrine and its relevance in medical device product liability litigation.
United States Court of Appeals for the Ninth Circuit
Case Name:
Stengel v. Medtronic Inc.
Adverse Event
Biomedical Equipment
Causation Analysis
FDA Regulation
Implant
Implantable Medical Devices
Infusion Pump
Product Failure
Product Safety
Safety Warnings
Stengel v. Medtronic Inc., 704 F.3d 1224 (9th Cir. 2013), is a significant appellate case addressing federal preemption in medical device litigation and the ability to pursue state-law failure-to-warn claims. The lawsuit involved the Medtronic SynchroMed EL, an implantable drug infusion pump approved through the U.S. Food and Drug Administration's (FDA) premarket approval (PMA) process. After Richard Stengel experienced complications allegedly linked to the device, the plaintiffs challenged Medtronic’s postmarket safety reporting practices. While biomedical engineering issues were relevant, the core legal question concerned whether a state-law claim that paralleled federal regulatory obligations could avoid preemption.
Richard Stengel, a former police officer, was implanted with the Medtronic SynchroMed EL, a Class III medical device intended for targeted drug delivery. The device had received FDA PMA approval and was designed to administer medication into the intrathecal space for chronic pain management.
After implantation, Stengel experienced serious medical complications, including inflammation and paralysis. These conditions were allegedly linked to a malfunction of the catheter component of the infusion pump. The incident raised questions about medical device safety, postmarket performance, and whether Medtronic had properly reported known risks to the FDA.
Stengel and his wife filed a civil lawsuit in federal court, asserting state-law causes of action for defective design and failure to warn. The district court dismissed the claims, ruling that they were preempted under the Medical Device Amendments (MDA) of 1976 due to the device’s FDA-approved status.
The U.S. Court of Appeals for the Ninth Circuit reversed the district court’s decision. It ruled that the plaintiffs’ failure-to-warn claim was not preempted because it was based on a state-law duty that paralleled federal regulations requiring manufacturers to report adverse events to the FDA. The case clarified the application of the “parallel claims” doctrine and its relevance in medical device product liability litigation.
Biomedical Engineering Expert Witness
These experts may have evaluated the design and mechanical reliability of the SynchroMed EL device. Their analysis typically includes mechanical failure modes, catheter function, and biocompatibility.
FDA Regulatory Compliance Expert Witness
Specialists in FDA medical device compliance assess whether the manufacturer met postmarket reporting duties and conformed with federal regulations, particularly regarding adverse event disclosures.
Medical Causation Expert Witness (Neurology and Orthopedics)
Clinical experts provide testimony on whether the patient’s outcome such as paralysis was causally linked to the alleged device malfunction or complications.
Federal Preemption in Medical Device Cases: Claims involving FDA-approved Class III devices may be preempted unless they assert a state-law duty that parallels a federal requirement.
Parallel Claims Exception: The Ninth Circuit reaffirmed that failure-to-warn claims based on violations of FDA reporting duties can survive preemption if they mirror federal obligations.
Importance of Postmarket Surveillance: Manufacturer responsibilities do not end at approval. Ongoing safety monitoring and adverse event reporting are crucial in liability risk and litigation.
Interdisciplinary Expert Collaboration: Medical device litigation often depends on input from biomedical engineers, compliance specialists, and clinical experts to clarify technical and medical questions.
Stengel v. Medtronic contributes to the evolving legal landscape of FDA preemption and parallel claims in product liability cases. The case highlights the conditions under which state-law claims may proceed against manufacturers of FDA-approved devices. For attorneys handling medical device failure cases, this decision underscores the need to align claims with federal standards and build litigation strategies supported by credible expert testimony.
Was Medtronic found liable in this case?
No. The Ninth Circuit allowed the case to proceed but did not issue a ruling on liability.
What type of medical device was involved?
The Medtronic SynchroMed EL, a Class III implantable infusion pump for drug delivery.
What does this case say about FDA preemption?
It affirms that while many claims may be preempted, failure-to-warn claims that reflect federal requirements such as adverse event reporting may still be allowed.
How do biomedical engineering experts support litigation in these cases?
They evaluate product design, performance failures, and mechanical risks that may contribute to patient injury.
What precedent does this case set?
The ruling reinforces the viability of parallel claims in medical device litigation and outlines when preemption may not apply.
Biomedical Engineering Expert Witness
These experts may have evaluated the design and mechanical reliability of the SynchroMed EL device. Their analysis typically includes mechanical failure modes, catheter function, and biocompatibility.
FDA Regulatory Compliance Expert Witness
Specialists in FDA medical device compliance assess whether the manufacturer met postmarket reporting duties and conformed with federal regulations, particularly regarding adverse event disclosures.
Medical Causation Expert Witness (Neurology and Orthopedics)
Clinical experts provide testimony on whether the patient’s outcome such as paralysis was causally linked to the alleged device malfunction or complications.
Federal Preemption in Medical Device Cases: Claims involving FDA-approved Class III devices may be preempted unless they assert a state-law duty that parallels a federal requirement.
Parallel Claims Exception: The Ninth Circuit reaffirmed that failure-to-warn claims based on violations of FDA reporting duties can survive preemption if they mirror federal obligations.
Importance of Postmarket Surveillance: Manufacturer responsibilities do not end at approval. Ongoing safety monitoring and adverse event reporting are crucial in liability risk and litigation.
Interdisciplinary Expert Collaboration: Medical device litigation often depends on input from biomedical engineers, compliance specialists, and clinical experts to clarify technical and medical questions.
Stengel v. Medtronic contributes to the evolving legal landscape of FDA preemption and parallel claims in product liability cases. The case highlights the conditions under which state-law claims may proceed against manufacturers of FDA-approved devices. For attorneys handling medical device failure cases, this decision underscores the need to align claims with federal standards and build litigation strategies supported by credible expert testimony.
Was Medtronic found liable in this case?
No. The Ninth Circuit allowed the case to proceed but did not issue a ruling on liability.
What type of medical device was involved?
The Medtronic SynchroMed EL, a Class III implantable infusion pump for drug delivery.
What does this case say about FDA preemption?
It affirms that while many claims may be preempted, failure-to-warn claims that reflect federal requirements such as adverse event reporting may still be allowed.
How do biomedical engineering experts support litigation in these cases?
They evaluate product design, performance failures, and mechanical risks that may contribute to patient injury.
What precedent does this case set?
The ruling reinforces the viability of parallel claims in medical device litigation and outlines when preemption may not apply.
Adverse Event
Biomedical Equipment
Causation Analysis
FDA Regulation
Implant
Implantable Medical Devices
Infusion Pump
Product Failure
Product Safety
Safety Warnings
Medical Devices, +4
Healthcare
Healthcare, +4
Healthcare